Collagenase SANTYL® Ointment | Mechanism of Action

About SANTYL^® Ointment
MOA Video
Case Studies
Additional Resources

Mechanism of Action Video

Occasional slight transient erythema has been noted in surrounding tissue when applied outside the wound. One case of systemic hypersensitivity has been reported after 1 year of treatment with collagenase and cortisone.
Use of Collagenase SANTYL^® Ointment should be terminated when debridement is complete and granulation tissue is well established.
See complete prescribing information for more details.

Application Protocol for
SANTYL^® Ointment

FAQs

Answers to Frequently Asked
Questions About SANTYL^®
Ointment

SANTYL^® Home | Legal Disclaimer

SANTYL^® is a registered trademark of Healthpoint, Ltd. Healthpoint and design is a registered trademark of Healthpoint, Ltd.
© 2010 Healthpoint, Ltd. All rights reserved.
The information on this site is intended for customers, patients, and healthcare professionals in the United States only. All information, including the Prescribing Information for Collagenase SANTYL^® Ointment, abides by the laws, regulatory requirements, and medical practices for the United States only and may not be appropriate for use outside of the United States.